MISSISSAUGA, Ont. (CP) - Nuvo Research Inc. (TSX:NRI) has received an "approvable" letter from the U.S. Food and Drug Administration, outlining how full approval can be obtained for Pennsaid, an anti-inflammatory treatment for osteoarthritis in the knee.
FULL STORY

Source: Canadian Online Health News